March 20, 2019
Authored and Edited by Megan L. Meyers; M. Andrew Holtman, Ph.D.
On March 7, 2019 FDA updated the Center for Drug Evaluation and Research (CDER) Manual of Policies on Procedures (MAPP) for Nonproprietary Naming of Biological Products. The material is referred to as MAPP 6720.5.
This material describes procedures for handling requests for nonproprietary name suffix review for INDs and BLAs for originator biological products, related biological products, and biosimilar products to be used in the CDER. Reference is made to the final FDA guidance issued in January of 2017 regarding nonproprietary naming of biological products, which notes that the nonproprietary name designated for each originator biological product, related biological product, and biosimilar product is a proper name that is a combination of the core name and a distinguishing suffix that is: (1) designated by FDA, (2) devoid of meaning, and (3) composed of four lowercase letters.
In particular, Division of Medication Error Prevention and Analysis (DMEPA) officials in the Office of Surveillance and Epidemiology (OSE) are authorized to take regulatory actions related to the approval of drugs for human use that are the subject of a BLA under CDER jurisdiction, including decisional letters regarding review of the nonproprietary name suffix candidate. The policy and procedure material discusses the responsibilities of various offices within the CDER regarding review of nonproprietary name suffixes identified by FDA or proposed by a sponsor. Some designated responsibilities are as follows:
More information regarding nonproprietary naming of biological products can be found here. The material additionally may be applicable to interchangeable biological products as discussed in a recent FDA guidance.
Readers are encouraged to read MAPP 6720.5, also available on FDA’s website.
Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
INCONTESTABLE® Blog
April 19, 2024
INCONTESTABLE® Blog
Winning the Battle but Not the War: Disclaimer Requirement Overturned, Section 2(d) Objection Upheld
March 28, 2024
Conference
2nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities
March 20, 2024
Boston
Articles
Cracking the Code: How Do Courts Decide Where Internationally Stored Source Code Should Be Reviewed?
February 20, 2024
Webinar
February 15, 2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.